{"filing":{"accession_number":"0001213900-26-111393","cik":"0002023311","ticker":"AAPG","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"ea0309299-6k_ascentage.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023311/000121390026111393/ea0309299-6k_ascentage.htm"},"events":[{"id":36857,"run_id":33980,"accession_number":"0001213900-26-111393","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Ascentage Pharma announced that lisaftoclax (APG-2575) has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib, a significant regulatory milestone that accelerates development and enables priority review and potential conditional approval pathways.","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":[{"id":41408,"accession_number":"0001213900-26-111393","item_number":"EX-99.1","item_title":"ea030929901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ascentage Pharma announced that lisaftoclax (APG-2575) has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib. This is a significant regulatory milestone that accelerates development and enables priority review and potential conditional approval pathways, but it is not a discrete event type in the taxonomy (not an approval itself, not an M\u0026A activity, not a financing event). The BTD represents material operational/strategic progress in the company's drug development pipeline and regulatory strategy, warranting classification as operational_other rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:56:40.929090+00:00","company_name":"","ticker":null,"filing_date":""},{"id":41409,"accession_number":"0001213900-26-111393","item_number":"EX-99.2","item_title":"ea030929901ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ascentage Pharma's Lisaftoclax has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib. This is a material regulatory milestone that accelerates development and review of an innovative drug candidate addressing an unmet clinical need, but it is not a discrete event type in the taxonomy (not an approval, not a clinical trial result, not a financing event). The BTD designation is a significant operational/regulatory achievement that would affect investor assessment of the company's pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:56:40.929090+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41408,"accession_number":"0001213900-26-111393","item_number":"EX-99.1","item_title":"ea030929901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ascentage Pharma announced that lisaftoclax (APG-2575) has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib. This is a significant regulatory milestone that accelerates development and enables priority review and potential conditional approval pathways, but it is not a discrete event type in the taxonomy (not an approval itself, not an M\u0026A activity, not a financing event). The BTD represents material operational/strategic progress in the company's drug development pipeline and regulatory strategy, warranting classification as operational_other rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:56:40.929090+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-10-21"},{"id":41409,"accession_number":"0001213900-26-111393","item_number":"EX-99.2","item_title":"ea030929901ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ascentage Pharma's Lisaftoclax has been granted Breakthrough Therapy Designation (BTD) by China's NMPA for treatment-naïve CLL/SLL in combination with acalabrutinib. This is a material regulatory milestone that accelerates development and review of an innovative drug candidate addressing an unmet clinical need, but it is not a discrete event type in the taxonomy (not an approval, not a clinical trial result, not a financing event). The BTD designation is a significant operational/regulatory achievement that would affect investor assessment of the company's pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:56:40.929090+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-10-21"}]}